Figure 2From: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]Changes from baseline on primary endpoints: a) tender joint counts; b) swollen joint counts; c) patient global assessments of disease activity; d) investigator global assessments of disease activity. S = screening visit, R = randomization (baseline) visit; SE = standard error. Screening (S) to randomization (R) = washout period for prior NSAID therapy. Empty circle = placebo, empty triangle = etoricoxib 90 mg, solid diamond = naproxen 1000 mg. A last-observation-carried-forward approach was used for missing values.Back to article page